PD-1/PD-L1 inhibitors, such as nivolumab and atezolizumab, achieved a considerable success in dealing with advanced NSCLC via blocking PD-1/PD-L1 [10, 11]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.